Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 360

1.

Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation.

González-Suarez I, Rodríguez de Antonio L, Orviz A, Moreno-García S, Valle-Arcos MD, Matias-Guiu JA, Valencia C, Jorquera Moya M, Oreja-Guevara C.

Brain Behav. 2017 Mar 14;7(4):e00671. doi: 10.1002/brb3.671. eCollection 2017 Apr.

2.

Progressive Multifocal Leukoencephalopathy and Rheumatoid Arthritis Treatments.

Clavel G, Moulignier A, Semerano L.

Joint Bone Spine. 2017 Mar 16. pii: S1297-319X(17)30041-6. doi: 10.1016/j.jbspin.2017.03.002. [Epub ahead of print]

PMID:
28323224
3.

Stability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.

Hegen H, Auer M, Bsteh G, Di Pauli F, Plavina T, Walde J, Deisenhammer F, Berger T.

PLoS One. 2017 Mar 20;12(3):e0174005. doi: 10.1371/journal.pone.0174005. eCollection 2017.

4.

Long-term effectiveness and safety of natalizumab in a Portuguese population.

Correia I, Batista S, Galego O, Marques IB, Jesus-Ribeiro J, Martins AI, Nunes C, Macário MC, Cunha L, Sousa L.

Int Immunopharmacol. 2017 May;46:105-111. doi: 10.1016/j.intimp.2017.03.006. Epub 2017 Mar 7.

PMID:
28282574
5.

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.

Landi D, De Rossi N, Zagaglia S, Scarpazza C, Prosperini L, Albanese M, Buttari F, Mori F, Marfia GA, Sormani MP, Capra R, Centonze D; Italian PML study group..

Neurology. 2017 Mar 21;88(12):1144-1152. doi: 10.1212/WNL.0000000000003740. Epub 2017 Feb 22.

PMID:
28228569
6.

Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidence.

Bacchetta F, Mathias A, Schluep M, Du Pasquier R.

Mult Scler. 2017 Feb;23(2):300-303. doi: 10.1177/1352458516670734.

PMID:
28165319
7.

Update on disease-modifying therapies for multiple sclerosis.

Vargas DL, Tyor WR.

J Investig Med. 2017 Jan 27. pii: jim-2016-000339. doi: 10.1136/jim-2016-000339. [Epub ahead of print]

PMID:
28130412
8.

Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine.

Alstadhaug KB, Fykse Halstensen R, Odeh F.

J Clin Virol. 2017 Mar;88:17-20. doi: 10.1016/j.jcv.2016.12.005. Epub 2016 Dec 14.

PMID:
28095350
9.

Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.

Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, Garcia-Martinez MA, Arias-Leal AM, García-Montojo M, Pérez-Pérez S, Arroyo R, Alvarez-Lafuente R.

Eur J Clin Invest. 2017 Feb;47(2):158-166. doi: 10.1111/eci.12721.

PMID:
28036121
10.

Significance of Interviral Recombination as Novel Mechanism for Extending Viral Disease Repertoire.

Johnson EM, Daniel DC.

Brain Disord Ther. 2016 Oct;5(3). pii: 127. doi: 10.4172/2168-975X.1000217. Epub 2016 Jun 23.

11.

Natalizumab treatment of multiple sclerosis: new insights.

Delbue S, Comar M, Ferrante P.

Immunotherapy. 2017 Jan;9(2):157-171. doi: 10.2217/imt-2016-0113. Epub 2016 Dec 22.

PMID:
28004598
12.

Progressive Multifocal Leukoencephalopathy in a Multiple Sclerosis Patient Diagnosed after Switching from Natalizumab to Fingolimod.

Sinnecker T, Othman J, Kühl M, Metz I, Niendorf T, Kunkel A, Paul F, Wuerfel J, Faiss J.

Case Rep Neurol Med. 2016;2016:5876798. Epub 2016 Nov 22.

13.

Safety and Efficacy of Natalizumab in Japanese Patients with Relapsing-Remitting Multiple Sclerosis: Open-Label Extension Study of a Phase 2 Trial.

Saida T, Kira JI, Kishida S, Yamamura T, Ohtsuka N, Ling Y, Torii S, Lucas N, Kuesters G, Steiner D, Tibung JT; Natalizumab Trial Principal Investigators..

Neurol Ther. 2016 Dec 5. [Epub ahead of print]

PMID:
27921221
14.

JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.

Uleri E, Ibba G, Piu C, Caocci M, Leoni S, Arru G, Serra C, Sechi G, Dolei A.

J Neurovirol. 2017 Apr;23(2):226-238. doi: 10.1007/s13365-016-0492-x. Epub 2016 Nov 3.

PMID:
27812788
15.

[Progressive multifocal leukoencephalopathy].

Warnke C, Wattjes MP, Adams O, Hartung HP, Martin R, Weber T, Stangel M.

Nervenarzt. 2016 Dec;87(12):1300-1304. Review. German.

PMID:
27730274
16.

Polyomaviruses.

Cook L.

Microbiol Spectr. 2016 Aug;4(4). doi: 10.1128/microbiolspec.DMIH2-0010-2015.

PMID:
27726799
17.

Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.

Saylor D, Venkatesan A.

Curr Infect Dis Rep. 2016 Nov;18(11):33. doi: 10.1007/s11908-016-0543-8. Review.

PMID:
27686675
18.

[Fingolimod: effectiveness and safety in routine clinical practice. An observational, retrospective, multi-centre study in the province of Alicante].

Mallada J, Perez-Carmona N, Berenguer-Ruiz L, Sanchez-Perez R, Martin-Gonzalez R, Sola-Martinez D, Mola S, Lopez-Arlandis JM, Vela-Yebra R, Gabaldon-Torres L, Freire-Alvarez E, Garcia-Escriva A, Sempere AP.

Rev Neurol. 2016 Sep 5;63(s01):S27-S34. Spanish.

PMID:
27658433
19.

Predictors of Response to Multiple Sclerosis Therapeutics in Individual Patients.

Hegen H, Auer M, Deisenhammer F.

Drugs. 2016 Oct;76(15):1421-1445. Review.

PMID:
27653757
20.

Influenza vaccination increases anti-JC virus antibody levels during treatment with Natalizumab: Case report.

Miranda Acuña JA, Weinstock-Guttman B.

Mult Scler Relat Disord. 2016 Sep;9:54-5. doi: 10.1016/j.msard.2016.06.014. Epub 2016 Jun 28.

PMID:
27645344

Supplemental Content

Loading ...
Support Center